Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes

被引：0
|
作者：
Marso
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：159 / 159
页数：1
相关论文
共 50 条
  • [1] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [2] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Ipp, Eli
    Genter, Pauline
    Childress, Kristin
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 891
  • [3] Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes
    Temporelli, Pier Luigi
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2025, 27 : i1 - i5
  • [4] A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
    Yanai, Hidekatsu
    Hakoshima, Mariko
    Adachi, Hiroki
    Katsuyama, Hisayuki
    CARDIOLOGY RESEARCH, 2022, 13 (05) : 303 - 308
  • [5] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Husain, Mansoor
    Birkenfeld, Andreas L.
    Donsmark, Morten
    Dungan, Kathleen
    Eliaschewitz, Freddy G.
    Franco, Denise R.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Mosenzon, Ofri
    Pedersen, Sue D.
    Tack, Cees J.
    Thomsen, Mette
    Vilsboll, Tina
    Warren, Mark L.
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09): : 841 - 851
  • [6] Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (05) : 489 - 492
  • [7] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
    Ugo Di Folco
    Noemi Vallecorsa
    Maria Rosaria Nardone
    Angelo Lauria Pantano
    Claudio Tubili
    Acta Diabetologica, 2022, 59 : 1287 - 1294
  • [8] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
    Di Folco, Ugo
    Vallecorsa, Noemi
    Nardone, Maria Rosaria
    Pantano, Angelo Lauria
    Tubili, Claudio
    ACTA DIABETOLOGICA, 2022, 59 (10) : 1287 - 1294
  • [9] Type-2 Diabetes: Examination of cardiovascular Risk Profile of oral Semaglutide
    Lichert, Frank
    DIABETOLOGIE UND STOFFWECHSEL, 2019, 14 (06)
  • [10] Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    McGuire, D. K.
    Marx, N.
    Mulvagh, S. L.
    Deanfield, J. E.
    Inzucchi, S. E.
    Pop-Busui, R.
    Mann, J. F. E.
    Emerson, S. S.
    Poulter, N. R.
    Engelmann, M. D. M.
    Ripa, M. S.
    Hovingh, G. K.
    Brown-Frandsen, K.
    Bain, S. C.
    Cavender, M. A.
    Gislum, M.
    David, J-P
    Buse, J. B.
    SOUL Study Group
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
12345